Related references
Note: Only part of the references are listed.ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Laura Cato et al.
CANCER CELL (2019)
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
Mercedes Marin-Aguilera et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes
Mohammed Nimir et al.
CELLS (2019)
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2019)
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Docetaxel promotes the generation of anti-tumorigenic human macrophages
Camilla Rydberg Millrud et al.
EXPERIMENTAL CELL RESEARCH (2018)
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2018)
Androgen receptor mRNA analysis from whole blood: a low-cost strategy for detection of androgen receptor gene splicing defects
Juliana M. Silva et al.
CLINICAL GENETICS (2018)
Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis
Heng Li et al.
EUROPEAN UROLOGY FOCUS (2018)
Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
Fangfang Qu et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
Tilman Todenhoefer et al.
JOURNAL OF UROLOGY (2017)
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
Oscar Reig et al.
EUROPEAN UROLOGY (2016)
Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells
Eiman Mukhtar et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Role of androgens in dhea-induced rack1 expression and cytokine modulation in monocytes
Emanuela Corsini et al.
IMMUNITY & AGEING (2016)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2016)
Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer
Takumi Takeuchi et al.
RESEARCH AND REPORTS IN UROLOGY (2016)
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
Wendy Onstenk et al.
EUROPEAN UROLOGY (2015)
Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
Mercedes Marin-Aguilera et al.
ONCOTARGET (2015)
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Emmanuel S. Antonarakis et al.
JAMA ONCOLOGY (2015)
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani-Mulero et al.
CANCER RESEARCH (2014)
Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells
William C. Krause et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Identification of androgen receptor variants in testis from humans and other vertebrates
S. S. Laurentino et al.
ANDROLOGIA (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Androgen Receptor Influences on Body Defense System via Modulation of Innate and Adaptive Immune Systems Lessons from Conditional AR Knockout Mice
Jiann-Jyh Lai et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Meng-Lei Zhu et al.
CANCER RESEARCH (2010)
Expansion of the eukaryotic proteome by alternative splicing
Timothy W. Nilsen et al.
NATURE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor
Kuang-Hsiang Chuang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
The immunological effects of taxanes
OTM Chan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
Share Paper
